Melanoma

Researchers test new therapy for advanced melanoma

Melanoma is a particularly deadly form of skin cancer very resistant to treatment. Researchers at H. Lee Moffitt Cancer Center & Research Institute and the University of South Florida are testing a promising new therapy that prompts the immune system to aid in the fight against melanoma tumors. "This is a milestone clinical trial because it is the first time that electroporation is bei...

NCI Researchers Confirm the Effectiveness of Immunotherapy Approach to Treating Melanoma

A team of researchers, led by Steven A. Rosenberg, M.D., at the National Cancer Institute, part of the National Institutes of Health, have found that patients with advanced melanoma who had not responded to previous therapies experienced a significant reduction in the size of their cancers as a result of receiving a new immunotherapy. This immunotherapy consisted of a combination of chemotherapy...

Engineered skin offers clues to melanoma development

When it comes to the deadly skin cancer melanoma, studying functional tissue rather than cell lines may better provide insight into the disease's development, according to new research from a Howard Hughes Medical Institute predoctoral fellow at Stanford University School of Medicine. Though multiple genetic alterations are associated with melanoma development, scientists have not been abl...

Newfound roadblock to interferon effectiveness against malignant melanoma

Researchers have uncovered a significant contributing factor to interferon resistance of malignant melanoma cells. The finding represents a step forward in understanding the molecular events that govern the growth of this type of cancer and the changes in gene expression and cellular signaling that underlie resistance to established therapies. Malignant melanoma is the deadliest form of sk...

Protein amplification in melanoma is possible drug target

A newly discovered gene mutation may account for many cases of immune deficiency, in particular two syndromes known as immunoglobulin A (IgA) deficiency and Common Variable Immunodeficiency (CVID), report researchers in the July issue of Nature Genetics. The discovery may lead to a new diagnostic test for these conditions, which make people highly susceptible to infections and often go unrecogniz...

More>>

Melanoma at Biology Products

Mouse Anti-Human Melanoma gp100 Monoclonal Antibody, Unconjugated, Clone SPM142 from ABR-Affinity BioReagents

Description:-20 C, Avoid Freeze/Thaw Cycles...
Company:ABR-Affinity BioReagents

Rabbit Anti-Human Melanoma antigen, family C, 1 (MAGEC1) Polyclonal Antibody, Unconjugated from Lifespan Biosciences

Description:Melanoma Antigen, Family C, 1 (MAGEC1) Rabbit anti-Human Polyclonal Antibody Long term: -20C; Short term: +4C...
Company:Lifespan Biosciences

Melanoma at Biology Technology

No data found

Search Melanoma biology technology at Google

Search Melanoma biology technology at Yahoo

Search Melanoma biology technology at Msn

Melanoma at Medicine News

UV Radiation induces Melanoma

Children who suffer sunburn very early in life are far more likely to suffer the most dangerous form of skin cancer, suggest researchers. In humans, melanocytes, the pigment-producing skin cells where melanoma develops, are on the surface of the skin. It is thought that some melanomas are the result of genetic damage caused when the UV radiation strikes these pigment cells. Babies and young child...

Reduction in melanoma death rate

In the last 25 years, in New York, there has been a declining trend in mortality from malignant melanoma, although its frequency has increased. Researchers at the University of Texas, have analysed data on malignant melanoma, the deadliest form of skin cancer, between 1981 and 1999.// They find there has been a 200 per cent increase in cases among men - from 2.0 cases per 150,000 population to 12...

Latest device for identifying Melanomas

A research from Australian company has finalized development of a digital screening device it says will take the guesswork out of diagnosing melanomas, the third most common cancer in Australia. Victor Skladnev, managing director of Polartechnics said that in terms of its ability to diagnose melanomas, it matches top specialists.// Image analysis and computer-aided diagnostic software...

Specialist surgeon not imperative in melanoma

According to a new study it is observed that the background of the surgeon does not affect the outcome in melanoma. Researchers at the University of Glasgow have surveyed 4,139 melanoma patients who had their tumour removed between 1979 and 1999.// They found the outcomes to be similar, whether the operating surgeon had a background in dermatology, cosmetic work, or general surgery. This is in co...

Tumour marker for melanoma found

According to a recent study it is observed that a molecular marker is linked to prognosis in malignant melanoma. In cancer research today, there is increasing emphasis on looking for molecules// specific to that cancer which might aid in monitoring the progression of the disease. Scientists at New York University now report on a molecular marker called HDM2 which appears to be important in tracki...

More>>

Melanoma at Medicine Products

No data found

Search Melanoma medicine products at Google

Search Melanoma medicine products at Yahoo

Search Melanoma medicine products at Msn

Melanoma at Medicine Technology

IDM Pharma Presents Preliminary Results from Phase II UVIDEM Melanoma Vaccine Clinical Trial

- Results show UVIDEM was well-tolerated with signs of durabledisease control in advanced melanoma patients - IRVINE, Calif., June 05, 2007 /PRNewswire-FirstCall/ -- IDMPharma, Inc. today presented preliminary results from a Phase IIUVIDEM (IDD-3) melanoma vaccine clinical trial (DC-MEL-202). Theresults showed that UVIDEM was well tolerated with evidence ofefficacy and induction of immune...

Synta Presents Results for STA-4783 in Metastatic Melanoma Showing Improvement in Overall Survival

LEXINGTON, Mass.--(BUSINESS WIRE)--Jun 5, 2007 - SyntaPharmaceuticals Corp., (NASDAQ: SNTA) a biopharmaceutical companyfocused on discovering, developing, and commercializing smallmolecule drugs to treat severe medical conditions, today announcedencouraging results from the analysis of overall survival (OS) timefor patients in the Company's double-blind, randomized, controlled,multi-center...

Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab

Clinical Phase I and II data presented at American Society ofClinical Oncology (ASCO) 2007 Annual Meeting CHICAGO, June 05, 2007 /PRNewswire-FirstCall/ -- Medarex, Inc.and Bristol-Myers Squibb Company today presented results frommultiple clinical studies of ipilimumab (MDX-010), aninvestigational immunotherapy, for patients with advanced melanoma.The results demonstrated an anti-tumor res...

Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival

CHICAGO – June 2, 2007 – Long-term treatment withpegylated interferon alfa-2b in stage III melanoma had asignificant and sustained impact on relapse-free survival (RFS),according to the results of the largest adjuvant trial everconducted in patients with stage III melanoma. Results of the PhaseIII study, led by...

Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO

HAYWARD, Calif., June 04, 2007 /PRNewswire-FirstCall/ -- KosanBiosciences Incorporated presented preliminary data from a Phase 2monotherapy trial showing that tanespimycin demonstrated antitumoractivity and tolerability in patients with metastatic melanoma,including one patient with a BRAF mutation (V600E) who had failedprior chemotherapy (within 6 weeks of initiation) and while ontanesp...

More>>

Melanoma at Medicine Dictionary

Melanoma

can occur anywhere...

Malignant melanoma

Alternate Names <a href...